Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07158918 · ClinicalTrials.gov registry record · Phase 1
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
A Phase 1 study of Solid Tumors, sponsored by ABL Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
- 6
- Study locations
NCT07158918: Recruiting Phase 1 study of Solid Tumors, sponsored by ABL Bio.
NCT07158918 is a Phase 1 study of Solid Tumors that is actively recruiting participants, run by ABL Bio. The registered enrollment target is 65 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (77% lower). The trial reports 6 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07158918, a Phase 1 study of Solid Tumors, is actively recruiting participants, sponsored by ABL Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study is to assess the safety and antitumor activity of ABL103 plus pembrolizumab, with or without taxane, in advanced or metastatic solid tumors.
Conditions Studied
Interventions
- DRUG KEYTRUDA® (pembrolizumab)
- DRUG ABL103
- DRUG Taxane
Study Locations (6)
Other
- Seoul National University Bundang Hospital - Seongnam
- Seoul National University Hospital - Seoul
- Asan Medical Center - Seoul
- Samsung Medical Center - Seoul
Ohio
- UH Cleveland Medical Center - Cleveland
Victoria
- PASO Medical - Frankston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2025-08-06 |
| Est. Completion | 2027-12-02 |
| Phase | Phase 1 |
What NCT07158918 shows while recruiting
NCT07158918 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which KEYTRUDA® (pembrolizumab) is the first listed.
NCT07158918 lists 6 locations in 3 states (Other, Ohio, Victoria).
Frequently Asked Questions
What is clinical trial NCT07158918 about?
NCT07158918 is a clinical study titled "ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors". This study is to assess the safety and antitumor activity of ABL103 plus pembrolizumab, with or without taxane, in advanced or metastatic solid tumors.
What is the current status of trial NCT07158918?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2025-08-06. Estimated completion is 2027-12-02.
What conditions does trial NCT07158918 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT07158918?
The interventions under investigation include: KEYTRUDA® (pembrolizumab) (DRUG), ABL103 (DRUG), Taxane (DRUG).
Who is sponsoring clinical trial NCT07158918?
This trial is sponsored by ABL Bio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07158918 being conducted?
This trial has 6 study locations across Ohio, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07158918's enrollment target sits among peer trials
65 68th of 125 higher than 57 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
- NCT04028063 · 65 participants · Phase 2
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI